Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study

Condition:   Myocardial Infarction
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor 60 mg
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified August 2017

Index of Microcirculatory Resistance After Immediate Versus Deferred Stenting in Patients With Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Procedure: Deferred stenting
Sponsor:   Sejong General Hospital
Recruiting - verified August 2017

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Conditions:   ST Segment Elevation Myocardial Infarction;   Percutaneous Coronary Intervention
Interventions:   Drug: Cangrelor;   Other: Placebo
Sponsors:   University of Florida;   Chiesi Farmaceutici S.p.A.
Not yet recruiting - verified August 2017

COmprehensive Remote Ischemic Conditioning in Myocardial Infarction

Condition:   Myocardial Infarction, Anterior Wall
Intervention:   Device: comprehensive remote ischaemic conditioning
Sponsors:   China National Center for Cardiovascular Diseases;   Chinese Academy of Medical Sciences
Recruiting - verified August 2017

Angiotensin-(1-7) in Peripheral Arterial Disease

Condition:   Peripheral Arterial Disease
Interventions:   Drug: Angiotensin 1-7;   Drug: Saline
Sponsor:   Milton S. Hershey Medical Center
Recruiting - verified August 2017

Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   Tongji Hospital
Recruiting - verified August 2017

The Impact of Obesity on Postoperative Outcomes Following Cardiac Surgery

Conditions:   Obesity;   Cardiac Disease;   Cardiovascular Syndromes, Metabolic
Intervention:   Procedure: cardiac surgery
Sponsors:   Cardiovascular Research New Brunswick;   Horizon Health Network;   Maritime Heart Centre
Recruiting - verified August 2017

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin;   Drug: Empagliflozin;   Drug: Dapagliflozin;   Drug: Dipeptidyl Peptidase-4 Inhibitor (DPP-4);   Drug: Glucagon-Like Peptide-1 Agonist (GLP-1);   Drug: Thiazolidinedione (TZD);   Drug: Sulfonylureas;   Drug: Insulin
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2017

Remote Ischaemic Conditioning on Blood Pressure Control in Chronic Kidney Disease Patients

Conditions:   Chronic Kidney Diseases;   Hypertension;   Cardiovascular Diseases
Interventions:   Device: Active autoRIC® (CRIC Treatment);   Device: Sham Control autoRIC® (Sham Control)
Sponsors:   Singapore General Hospital;   Duke-NUS Graduate Medical School
Not yet recruiting - verified August 2017

CPR Training in Students to Increase Bystander Intervention in Out-of-hospital Cardiac Arrest.

Condition:   Coping Skills
Interventions:   Other: web course;   Other: CPR training
Sponsor:   Karolinska Institutet
Completed - verified August 2017

GLOBAL LEADERS Adjudication Sub-Study

Conditions:   Coronary Artery Disease;   Platelet-aggregation Inhibitors
Intervention:  
Sponsors:   University Hospital Inselspital, Berne;   European Cardiovascular Research Center
Active, not recruiting - verified August 2017

Subclinical Cardiovascular Disease in Psoriatic Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Atherosclerotic Cardiovascular Disease;   Thrombotic Vascular Disease
Intervention:   Drug: Aspirin and/or Atorvastatin
Sponsor:   New York University School of Medicine
Recruiting - verified August 2017

Transfusion Trigger After Operations in High Cardiac Risk Patients

Conditions:   Myocardial Infarction;   Coronary Revascularization;   Acute Renal Failure
Intervention:   Procedure: Blood Transfusion
Sponsor:   VA Office of Research and Development
Not yet recruiting - verified August 2017

Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis

Condition:   Coronary In-stnent Restenosis
Intervention:   Device: Treatment of restenosis
Sponsors:   Spanish Society of Cardiology;   Fundación de Investigación Biomédica - Hospital Universitario de La Princesa;   Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP);   Abbott Vascular
Recruiting - verified August 2017

Effects of Interval Physical Training on Expiratory Flow Limitation in Recent Myocardial Infarction

Conditions:   Expiratory Flow Limitation;   Recent Myocardial Infarction
Interventions:   Other: Interval Training (IT);   Other: Inspiratory Muscle Training (IMT)
Sponsors:   Federal University of Uberlandia;   Universidade Federal de Sao Carlos
Not yet recruiting - verified August 2017

Leaders Free III: BioFreedom™ Clinical Trial

Conditions:   Cardiac Death;   Myocardial Infarction;   Stent Thrombosis;   Bleeding;   Mortality
Intervention:   Device: BioFreedom™ BA9™ drug-coated stent
Sponsors:   Biosensors Europe SA;   European Cardiovascular Research Center
Not yet recruiting - verified August 2017

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Empagliflozin 10 mg;   Drug: Placebo Oral Tablet
Sponsors:   Medical University of Graz;   United Arab Emirates University;   Medical University of Vienna;   Landeskrankenhaus Feldkirch;   Krankenhaus der Barmherzigen Brüder Linz;   Kepler University Hospital;   Paracelsus Medical University
Recruiting - verified August 2017

The Effect of GRAVITY on Physiological Measurements During Invasive Coronary Angiography and Intervention

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Basildon and Thurrock University Hospitals NHS Foundation Trust;   Anglia Ruskin University
Recruiting - verified August 2017

OCT Registry in Patients With STEMI During PPCI

Condition:   ST Elevation Myocardial Infarction
Intervention:  
Sponsor:   Harbin Medical University
Recruiting - verified August 2017

China Resolute Integrity 34/38 mm Study

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:   Device: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)
Sponsor:   Medtronic Vascular
Active, not recruiting - verified August 2017

EROSION II: OCT Guided PPCI in STEMI

Condition:   STEMI - ST Elevation Myocardial Infarction
Intervention:  
Sponsor:   Harbin Medical University
Recruiting - verified August 2017

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
Interventions:   Device: Orbital Atherectomy;   Device: Balloon
Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
Recruiting - verified August 2017

Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System

Conditions:   Peripheral Arterial Disease;   Intermittent Claudication
Intervention:   Device: Bard® LifeStent® 5F Vascular Stent System
Sponsor:   C. R. Bard
Active, not recruiting - verified August 2017

Influence of Training Intensity in Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:   Other: Training intensity (workload) during ergospirometry
Sponsors:   Hasselt University;   Jessa Hospital
Recruiting - verified August 2017

Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation

Conditions:   Coronary Disease;   Coronary Stenoses
Interventions:   Device: quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro stent;   Device: intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro stent
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   Biotronik SE & Co. KG
Recruiting - verified August 2017

ABSORB Post-Approval Clinical Study

Condition:   Ischemic Heart Disease
Intervention:   Device: Absorb BVS
Sponsor:   Abbott Vascular
Not yet recruiting - verified August 2017

Validation of Epworth Richmond's Echocardiography Education Focused Year

Conditions:   Shock, Cardiogenic;   Cardiac Tamponade;   Pulmonary Embolism;   Hypovolemia
Intervention:   Behavioral: Epworth Richmond's Echocardiography Focused Year
Sponsors:   Epworth Healthcare;   University of Melbourne
Completed - verified August 2017

FINE75+: 5 Year Follow up

Conditions:   Non ST Elevation Myocardial Infarction (NSTEMI);   Frailty
Intervention:   Other: This is an observational study
Sponsor:   Linkoeping University
Completed - verified March 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified August 2017

Evaluation of Infarct Size With 3D Rotational Angiography

Condition:   Myocardial Infarction
Interventions:   Device: 3D RA;   Device: MRI
Sponsor:   Hospices Civils de Lyon
Recruiting - verified August 2017

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Angioplasty, Balloon, Coronary;   Platelet Aggregation Inhibitors
Interventions:   Drug: Prasugrel;   Drug: Ticagrelor
Sponsor:   Faculty Hospital Kralovske Vinohrady
Completed - verified August 2017

Reducing Acute Coronary Syndrome Patient Delay

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Text+Visual BCT-based intervention;   Behavioral: Text-only BCT intervention;   Behavioral: Leaflet information (control)
Sponsors:   Edinburgh Napier University;   University of Stirling;   University of Aberdeen;   University of Dundee;   The University of New South Wales
Recruiting - verified August 2017

The Impact of Post Stenting Balloon Dilatation on Coronary Microcirculation in STEMI Patients Undergoing PPCI

Condition:   ST-elevation Myocardial Infarction (STEMI)
Intervention:  
Sponsors:   Basildon and Thurrock University Hospitals NHS Foundation Trust;   Anglia Ruskin University
Recruiting - verified August 2017

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Drug: Tenecteplase;   Drug: Clopidogrel;   Procedure: Coronary angiography;   Procedure: Primary PCI
Sponsors:   Katholieke Universiteit Leuven;   Boehringer Ingelheim;   Life Sciences Research Partners;   Fund for Clinical Cardiovascular Research at LRD
Recruiting - verified August 2017

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL_112;   Other: Placebo
Sponsor:   CSL Behring
Completed - verified August 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

A Study of the ReCor Medical Paradise System in Clinical Hypertension

Conditions:   Hypertension;   Vascular Diseases
Interventions:   Device: The Paradise® Renal Denervation Ultrasound System;   Device: Sham Procedure
Sponsor:   ReCor Medical, Inc.
Recruiting - verified May 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2017

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified August 2017

Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions

Conditions:   Acute Myocardial Infarction;   Acute Coronary Syndrome
Intervention:   Other: APN-led Telemedicine
Sponsors:   National University Heart Centre, Singapore;   National University Hospital, Singapore
Recruiting - verified August 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Active, not recruiting - verified August 2017

Study Comparing the MiStent SES Versus the XIENCE EES Stent

Condition:   Coronary Stenosis
Interventions:   Device: MiStent;   Device: XIENCE EES
Sponsors:   ECRI bv;   Micell Technologies;   Stentys
Active, not recruiting - verified August 2017

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Condition:   Systemic Lupus Erthematosus
Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified July 24, 2017

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified August 2017

Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0

Condition:   Hypertension
Intervention:  
Sponsors:   National Human Genome Research Institute (NHGRI);   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified August 3, 2017

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified August 2017

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2017

Observational Study of the Association Between Periodontal Disease and Cardiovascular Disease

Conditions:   Periodontal Disease;   Coronary Artery Disease
Intervention:  
Sponsor:   Texas Tech University Health Sciences Center
Completed - verified August 2017

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   Cleveland Clinic Coordinating Center for Clinical Research (C5R);   Quintiles, Inc.
Active, not recruiting - verified August 2017

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Anakinra 100 mg;   Drug: Anakinra 100 mg;   Drug: Placebo
Sponsors:   Virginia Commonwealth University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2017

ABSORB STEMI: the TROFI II Study

Condition:   Acute ST Segment Elevation Myocardial Infarction
Intervention:   Device: Percutaneous Coronary Intervention
Sponsors:   ECRI bv;   Abbott Vascular;   Terumo Europe N.V.
Active, not recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Intensive Prevention Program After Myocardial Infarction

Conditions:   Myocardial Infarction;   Prevention Harmful Effects
Interventions:   Behavioral: Intensive Prevention Program;   Other: Standard medical and interventional therapy
Sponsors:   Herzzentrum Bremen;   Oldenburger Forschungs- und Entwicklungsinstitut für Informatik (OFFIS).
Completed - verified August 2017

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2017

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

Condition:   Type 2 Diabetes
Intervention:   Other: Glycemic clamping
Sponsor:   Medical College of Wisconsin
Terminated - verified April 2015

Normoglycemia and Neurological Outcome

Conditions:   Acute, Non-traumatic Subarachnoid Hemorrhage;   Intraparenchymal Hemorrhage;   Brain Injuries
Interventions:   Drug: Insulin;   Drug: Conventional insulin treatment
Sponsor:   University of Louisville
Terminated - verified August 2017

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition:   Cardiovascular Disease
Interventions:   Drug: Febuxostat;   Drug: Allopurinol
Sponsors:   Takeda;   Teijin America, Inc.
Completed - verified August 2017

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG

Conditions:   Myocardial Infarct;   Heart Failure
Intervention:   Procedure: Injection of stem cells at time of coronary artery bypass grafting
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Miltenyi Biotec, Inc.;   Centre de Recherche du Centre Hospitalier de l'Université de Montréal;   Maisonneuve-Rosemont Hospital
Completed - verified July 2015

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified August 2017

Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study

Conditions:   Myocardial Infarction;   Angina, Unstable
Intervention:  
Sponsors:   University Hospital, Basel, Switzerland;   Swiss National Science Foundation
Recruiting - verified August 2017

Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study

Conditions:   Coronary Artery Disease;   Coronary Artery Bypass Grafting
Interventions:   Drug: Aspirin;   Drug: Clopidogrel
Sponsors:   Hamilton Health Sciences Corporation;   Bristol-Myers Squibb
Completed - verified August 2017

Myocardial Damage In Patients With Cerebral Infarction

Condition:   Ischemic Stroke
Intervention:  
Sponsors:   Danish Heart Foundation;   Fonden for Lægevidenskabelig Forskning for Fyns Amt.;   Novo Nordisk A/S;   AJ Andersen og Hustrus Fond;   Overlægerådet Legatudvalg;   Raimond and Dagmar Ringgård-Bohn's Foundation;   Bankdirektør Hans Stener og hustru Agnes Steners legat;   Odense University Hospital
Completed - verified August 2017

The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases

Conditions:   Cardiovascular Diseases;   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Lifestyle consultation: weight control, diet, exercise;   Behavioral: Lifestyle consultation: weight control, diet, exercise
Sponsors:   Japan Foundation for the Promotion of International Medical Research Cooperation;   Japan Diabetes Foundation
Active, not recruiting - verified August 2017

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 31, 2017